CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 102,038	$ 65,500
Research and development incentive receivable	2,071	2,099
Prepaid expenses and other current assets	590	351
Total current assets	104,699	67,950
Property and equipment, net	16	20
Right of use assets, net	569	669
Research and development incentive receivable, net of current portion	272
Deferred costs		576
Other long term assets	15	30
Deposits	976	1,108
Total assets	106,547	70,353
Current liabilities:
Accounts payable	5,498	5,657
Accrued expenses	4,388	5,152
Lease liability - current portion	425	416
Total current liabilities	10,311	11,225
Non current liabilities:
Lease liability, net of current portion	152	262
Series X preferred stock warrant liability	40
Total liabilities	10,503	11,487
Mezzanine equity:
Series X Convertible Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 136,248 and 0 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively	67,715
Stockholders' equity:
Common stock, $0.001 par value; 240,000,000 shares authorized; 119,410,992 and 99,021,376 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively	119	99
Additional paid-in capital	387,886	376,807
Accumulated other comprehensive income	355	128
Accumulated deficit	(360,031)	(318,168)
Total stockholders' equity	28,329	58,866
Total liabilities, mezzanine equity and stockholders' equity	$ 106,547	$ 70,353